12 March 2021

Endobios has just published the first scientific manuscript related to its disruptive R&D in endosymbioses (core IP undisclosed):

A potential third‐order role of the host endoplasmic reticulum as a contact site in interkingdom microbial endosymbiosis and viral infection

23 October 2020

ENDOBIOS will present the pitch of its preclinical asset against epilepsy, at the Bio-Europe 2020 conference, integrated in the EIT Health Innostars Awards Grand Final.

16 June 2020

ENDOBIOS was shortlisted in the preselection phase of the Innovation Awards Roullier 2020, as a recognition of our proprietary method for the induction of cryptic antibiotics from microbial culturable sources (fungi, bacteria, microalgae), applicable in the agro, pharma or cosmetics industry.

9 June 2020

ENDOBIOS received an Innostars 2020 Award (EIT Health, European Union), as a recognition of our project related to the preclinical development of a marine-derived natural product as a drug candidate against epilepsy.

15 August 2019

ENDOBIOS is now eligible to apply for NIH grants (USA) as a foreign institution, after completing the registration procedures in the DUNS,, eRA Commons,  and NATO-NCAGE systems.